| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
9V
2 T Cells with a Synthetic Phosphoantigen in a Preclinical Nonhuman Primate Model
* Innate Pharma, Marseilles, France;
Institut National de la Santé et de la Recherche Médicale Unité 463, Centre Hospitalier Universitaire Nantes, Quai Moncousu, Nantes, France; and
Institut National de la Santé et de la Recherche Médicale Unité 563, CHU Purpan, Toulouse, France
V
9V
2+ cells represent the major population of T cells in primate blood and react in an MHC-unrestricted fashion to a set of low m.w. nonpeptide phosphoantigens. Two types of structurally related agonists have been discovered so far: the natural phosphoantigens (hydroxydimethyl allyl-pyrophosphate or isopentenyl-pyrophosphate (IPP)) acting directly on V9V2+ TCR and aminobisphosphonates, which block the mevalonate pathway in target cells, leading to accumulation of natural phosphoantigens that in turn activate V9V2+ cells. We demonstrate in the cynomolgus monkey that V9V2 can be manipulated in vivo with bromohydrin pyrophosphate (BrHPP)/Phosphostim, a potent synthetic agonist for which the mechanism of action is similar to natural phosphoantigens. Although of very short half-life, injection of BrHPP leads to strong activation of V9V2, inducing production of a high level of Th1 cytokines. Combination of BrHPP with low-dose rhIL-2 induces specific amplification of effector-memory peripheral V9V2 in blood in a dose-dependant manner. This transient response returns to baseline within 10–15 days. Successive infusions of BrHPP and rhIL-2 induce less vigorous expansions, suggesting a progressive exhaustion of the response. As no toxicity is detected with or without IL-2, this scheme represents a promising immunotherapeutic strategy for induction of systemic Th1 cytokines and massive expansion of T cell subset with antitumor and anti-infectious properties.
This article has been cited by other articles:
|
|
 |
|
  L. Shao, D. Huang, H. Wei, R. C. Wang, C. Y. Chen, L. Shen, W. Zhang, J. Jin, and Z. W. Chen Expansion, Reexpansion, and Recall-Like Expansion of V{gamma}2V{delta}2 T Cells in Smallpox Vaccination and Monkeypox Virus Infection J. Virol., November 15, 2009; 83(22): 11959 - 11965. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-C. Devilder, S. Allain, C. Dousset, M. Bonneville, and E. Scotet Early Triggering of Exclusive IFN-{gamma} Responses of Human V{gamma}9V{delta}2 T Cells by TLR-Activated Myeloid and Plasmacytoid Dendritic Cells J. Immunol., September 15, 2009; 183(6): 3625 - 3633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gertner-Dardenne, C. Bonnafous, C. Bezombes, A.-H. Capietto, V. Scaglione, S. Ingoure, D. Cendron, E. Gross, J.-F. Lepage, A. Quillet-Mary, et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies Blood, May 14, 2009; 113(20): 4875 - 4884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Huang, C. Y. Chen, Z. Ali, L. Shao, L. Shen, H. A. Lockman, R. E. Barnewall, C. Sabourin, J. Eestep, A. Reichenberg, et al. Antigen-specific V{gamma}2V{delta}2 T effector cells confer homeostatic protection against pneumonic plaque lesions PNAS, May 5, 2009; 106(18): 7553 - 7558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Devaud, E. Bilhere, S. Loizon, V. Pitard, C. Behr, J.-F. Moreau, J. Dechanet-Merville, and M. Capone Antitumor Activity of {gamma}{delta} T Cells Reactive against Cytomegalovirus-Infected Cells in a Mouse Xenograft Tumor Model Cancer Res., May 1, 2009; 69(9): 3971 - 3978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Thedrez, C. Harly, A. Morice, S. Salot, M. Bonneville, and E. Scotet IL-21-Mediated Potentiation of Antitumor Cytolytic and Proinflammatory Responses of Human V{gamma}9V{delta}2 T Cells for Adoptive Immunotherapy J. Immunol., March 15, 2009; 182(6): 3423 - 3431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gong, L. Shao, Y. Wang, C. Y. Chen, D. Huang, S. Yao, X. Zhan, H. Sicard, R. Wang, and Z. W. Chen Phosphoantigen-activated V{gamma}2V{delta}2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection Blood, January 22, 2009; 113(4): 837 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Li, K. Luo, and C. D. Pauza TNF-{alpha} Is a Positive Regulatory Factor for Human V{gamma}2V{delta}2 T Cells J. Immunol., November 15, 2008; 181(10): 7131 - 7137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. T. Spencer, G. Abate, A. Blazevic, and D. F. Hoft Only a Subset of Phosphoantigen-Responsive {gamma}9{delta}2 T Cells Mediate Protective Tuberculosis Immunity J. Immunol., October 1, 2008; 181(7): 4471 - 4484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Pitard, D. Roumanes, X. Lafarge, L. Couzi, I. Garrigue, M.-E. Lafon, P. Merville, J.-F. Moreau, and J. Dechanet-Merville Long-term expansion of effector/memory V{delta}2- {gamma}{delta} T cells is a specific blood signature of CMV infection Blood, August 15, 2008; 112(4): 1317 - 1324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Cummings, C. Cairo, C. Armstrong, C. E. Davis, and C. D. Pauza Impacts of HIV infection on V{gamma}2V{delta}2 T cell phenotype and function: a mechanism for reduced tumor immunity in AIDS J. Leukoc. Biol., August 1, 2008; 84(2): 371 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Chen, L. Shao, Z. Ali, J. Cai, and Z. W. Chen NSOM/QD-based nanoscale immunofluorescence imaging of antigen-specific T-cell receptor responses during an in vivo clonal V{gamma}2V{delta}2 T-cell expansion Blood, April 15, 2008; 111(8): 4220 - 4232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Ali, L. Shao, L. Halliday, A. Reichenberg, M. Hintz, H. Jomaa, and Z. W. Chen Prolonged (E)-4-Hydroxy-3-Methyl-But-2-Enyl Pyrophosphate-Driven Antimicrobial and Cytotoxic Responses of Pulmonary and Systemic V{gamma}2V{delta}2 T Cells in Macaques J. Immunol., December 15, 2007; 179(12): 8287 - 8296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Holderness, L. Jackiw, E. Kimmel, H. Kerns, M. Radke, J. F. Hedges, C. Petrie, P. McCurley, P. M. Glee, A. Palecanda, et al. Select Plant Tannins Induce IL-2R{alpha} Up-Regulation and Augment Cell Division in {gamma}{delta} T Cells J. Immunol., November 15, 2007; 179(10): 6468 - 6478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-J. Puan, C. Jin, H. Wang, G. Sarikonda, A. M. Raker, H. K. Lee, M. I. Samuelson, E. Marker-Hermann, L. Pasa-Tolic, E. Nieves, et al. Preferential recognition of a microbial metabolite by human V{gamma}2V{delta}2 T cells Int. Immunol., May 1, 2007; 19(5): 657 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Thompson and M. J. Rogers Bisphosphonates and {gamma}{delta} T-Cells: New Insights into Old Drugs IBMS BoneKEy, August 1, 2006; 3(8): 5 - 13. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
